论文部分内容阅读
目的探讨EBV Zta/IgG等抗体阳性鼻咽癌患者在1992分期和2008分期不同临床分期中分布的区别,为NPC分期系统的进一步研究提供参考。方法收集140例未经治疗的NPC患者的血清,用ELISA法检测Zta/IgG等抗体。分别统计分析1992分期和2008分期不同分期中EBV相关抗体阳性的NPC患者的例数,并比较不同分期中NPC患者的例数分布情况。结果 1992分期与2008分期中不同分期间Zta/IgG等抗体阳性例数的分布比较,差异均有统计学意义(P<0.05)。结论在1992分期中为临床Ⅲ期的阳性患者,如果按2008分期进行临床分期分类会更加趋向于被判定为Ⅳ期。或许从血清学方面在一定程度上反映了2008分期比1992分期更趋于合理性。
Objective To investigate the differences of the distribution of Epstein-Barr virus (EBV) Zta / IgG antibody-positive nasopharyngeal carcinoma (NPC) patients between 1992 stage and 2008 clinical stage, and to provide a reference for the further study of NPC staging system. Methods Serum samples of 140 untreated NPC patients were collected and antibodies such as Zta / IgG were detected by ELISA. The number of NPC patients with positive EBV-associated antibodies in 1992 staging and 2008 staging were statistically analyzed, and the number distribution of NPC patients in different stages was compared. Results There were significant differences in the distribution of Zta / IgG antibody positive cases between 1992 stage and 2008 stage (P <0.05). Conclusions In patients with positive clinical stage III in stage 1992, clinical stage classification by 2008 would be more likely to be judged as stage IV. Perhaps from a serological point of view to some extent reflects the 2008 staging more reasonable than the 1992 staging.